Search results
Showing 701 to 750 of 1834 results for carers
This guide outlines the main elements of the interim process and methods for the NICE clinical guideline updates using standing committees pilot programme, including details of the Clinical Guidelines Updates committee, which were agreed by the NICE Board in September 2013
Evidence-based recommendations on lumasiran (Oxlumo) for primary hyperoxaluria type 1 in people of all ages.
Membership details, terms of reference, future meeting dates and past meeting minutes for our 4 technology appraisal committees.
Membership details, terms of reference, future meeting dates and past meeting minutes for our 4 technology appraisal committees.
Transition between inpatient mental health settings and community or care home settings (QS159)
This quality standard covers transitions for children, young people and adults between mental health hospitals and their own homes, care homes or other community settings. It includes the period before, during and after a person is admitted to, and discharged from, a mental health hospital. It describes high-quality care in priority areas for improvement.
In development Reference number: GID-TA10998 Expected publication date: TBC
Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer [ID6433]
Awaiting development Reference number: GID-TA11489 Expected publication date: TBC
Navepegritide for treating achondroplasia in people 2 to 15 years [ID6538]
In development Reference number: GID-TA11699 Expected publication date: TBC
In development Reference number: GID-TA11583 Expected publication date: TBC
Awaiting development Reference number: GID-IPG10418 Expected publication date: TBC
In development Reference number: GID-TA11658 Expected publication date: TBC
Awaiting development Reference number: GID-TA11626 Expected publication date: TBC
In development Reference number: GID-TA11836 Expected publication date: TBC
Awaiting development Reference number: GID-TA11868 Expected publication date: TBC
Awaiting development Reference number: GID-TA11872 Expected publication date: TBC
In development Reference number: GID-TA11765 Expected publication date: TBC
Pimicotinib for treating tenosynovial giant cell tumours when systemic treatment is needed [ID6647]
In development Reference number: GID-TA11859 Expected publication date: TBC
In development Reference number: GID-TA11716 Expected publication date: TBC
In development Reference number: GID-TA11695 Expected publication date: TBC
Awaiting development Reference number: GID-TA11375 Expected publication date: TBC
Baxdrostat for treating uncontrolled or resistant hypertension [ID6623]
In development Reference number: GID-TA11818 Expected publication date: TBC
Beta interferons and glatiramer acetate for treating multiple sclerosis (TA527)
Evidence-based recommendations on beta interferons (Avonex, Betaferon, Extavia, Rebif) and glatiramer acetate (Copaxone) for treating multiple sclerosis in adults.
permanency (incorporating the perspectives of lookedafter children and permanency carers)? Any explanatory notes(if applicable) For a...
In development Reference number: GID-TA11535 Expected publication date: TBC
Awaiting development Reference number: GID-TA11723 Expected publication date: TBC
In development Reference number: GID-TA11812 Expected publication date: TBC
In development Reference number: GID-TA11590 Expected publication date: TBC
We are listening to your views on this Technology appraisal guidance. Comments close 11 February 2026.
We are listening to your views on this Technology appraisal guidance. Comments close 12 February 2026.
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and over ID6542
In development Reference number: GID-TA11525 Expected publication date: 10 February 2027
Awaiting development Reference number: GID-TA11878 Expected publication date: TBC
In development Reference number: GID-TA11869 Expected publication date: TBC
We are listening to your views on this Technology appraisal guidance. Comments close 19 February 2026.
In development Reference number: GID-TA11776 Expected publication date: TBC
Aficamten for treating symptomatic non-obstructive hypertrophic cardiomyopathy [ID6668]
Awaiting development Reference number: GID-TA11877 Expected publication date: TBC
Tell us what matters to you, your organisation or your community.
Tell us what matters to you, your organisation or your community.
In development Reference number: GID-TA10575 Expected publication date: TBC
Rocatinlimab for treating moderate to severe atopic dermatitis in people 12 years and over [ID6565]
In development Reference number: GID-TA11759 Expected publication date: TBC
In development Reference number: GID-TA11657 Expected publication date: 07 April 2027
In development Reference number: GID-TA11813 Expected publication date: TBC
Nipocalimab for treating generalised myasthenia gravis [ID6562]
In development Reference number: GID-TA11492 Expected publication date: TBC
Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]
In development Reference number: GID-TA11036 Expected publication date: TBC
Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]
Awaiting development Reference number: GID-TA11100 Expected publication date: TBC
Awaiting development Reference number: GID-TA11847 Expected publication date: TBC
Question Is a group-based parent training intervention for parents or carers of autistic children and young people clinically and cost...
In development Reference number: GID-TA11499 Expected publication date: TBC
Dementia. Patient decision aid on enteral (tube) feeding for people living with severe dementia
assessment, management and support for people living with dementia and their carers c NICE 2018. All rights reserved. Subject to Notice...
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency (HST26)
Evidence-based recommendations on eladocagene exuparvovec (Upstaza) for treating aromatic L-amino acid decarboxylase deficiency in people 18 months and over.
In development Reference number: GID-TA11224 Expected publication date: TBC